Dyne Therapeutics is a pioneering biotechnology company dedicated to transforming the lives of individuals facing genetically-driven neuromuscular diseases. With a commitment to innovation, Dyne specializes in developing nucleic acid therapies aimed at repairing muscle and halting disease progression. Their proprietary FORCE™ platform is designed to effectively deliver therapies directly to muscle tissues and the central nervous system, enhancing treatment efficacy for conditions like Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy Type 1 (DM1), and Facioscapulohumeral Muscular Dystrophy (FSHD).

Dyne's robust pipeline includes promising candidates such as DYNE-101, DYNE-251, and DYNE-302, which are currently in various stages of clinical trials. Beyond cutting-edge therapies, Dyne is deeply devoted to supporting patients, families, and caregivers affected by rare diseases, emphasizing community engagement and corporate responsibility. With a culture that values inclusivity and innovation, Dyne Therapeutics stands at the forefront of reshaping patient care for rare neuromuscular diseases through its life-changing therapies.